Recognizing the need for more progress in neglected disease research, WIPO Re:Search was formed in 2011 through the efforts of several of the world’s leading pharmaceutical companies, the World Intellectual Property Organization (WIPO), and BIO Ventures for Global Health. WIPO Re:Search is a multilateral, voluntary organization administered by the World Intellectual Property Organization in partnership with the non-profit organization BIO Ventures for Global Health (BVGH)In WIPO Re:Search, public and private sector organizations make valuableintellectual property available to qualified researchers seeking to develop new solutions for neglected tropical diseases, malaria, and tuberculosis.Providers offer access to intellectual property on a royalty-free basis for use and sale in all Least Developed Countries The intellectual property included in WIPO Re:Search includes free licenses for products, and providers agree to open up opportunities for discussions and the good faith negotiation for license termsWIPO Re:Search provides access to intellectual property for pharmaceutical compounds, technologies, and – most importantly – know-how can be a driving force for innovation in the search for new treatments for these devastating neglected diseases.
Newest Member is McGill University – Tim Geary
WIPO Re:Search focuses it’s efforts to facilitate the development of drugs, vaccines and diagnostics for these 21 neglected tropical diseases include malaria and tuberculosis.
The Partnership Hub is where members and the public can learn about available licensing and research collaboration opportunities, networking possibilities, and funding resources.To support the use of the resources made available in WIPO Re:Search, BIO Ventures for Global Health (BVGH) – a leading global health organization – serves as the nonprofit administrator of the Partnership Hub.In this role, BVGH reaches out to potential users and licensees of WIPO Re:Search resources so that all assets are used as productively as possible.Researchers access information via the WIPO Re:Search website (www.wipoReSearch.org), which is freely available to the public. Users with potential interest in a particular compound, technology, or service can contact BVGH directly on their website.From this connection, partnerships for new neglected disease projects can be created.
Switch to Roopa via this slide transition
Sharing Innovation in the Fight AgainstNeglected Tropical DiseasesWorld Intellectual Property OrganizationSecretariat Jennifer Dent – VP, Commercialization & Alliance ManagementBIO Ventures for Global HealthPartnership Hub Administrator www.wipoReSearch.org
What is WIPO Re:Search?• Led by the World Intellectual Property Organization in collaboration with BIO Ventures for Global Health• Makes intellectual property, know-how and other resources available to Member researchers working in the neglected tropical disease, malaria and tuberculosis fields• Provides free access and royalty free licenses – No upfront licensing fee – Royalty free products for Least Developed Countries• Facilitates collaboration to develop new drugs, vaccines, and diagnostics 3
WIPO Re:Search Roles WIPO Re:Search is a voluntary Consortium governed by its Members and a set of Guiding Principles • WIPO – Secretariat • BVGH – Partnership Hub Administrator • Members – Contribute and access intellectual property and other resources and partner to drive R&D for neglected tropical diseases, malaria and tuberculosis • Providers • Users • Supporters 4
Highlights of the Guiding Principles • Royalty-free licenses for neglected tropical disease, malaria and TB research and development for the least developed countries (LDCs) • Members will consider in good faith the issue of access to these products for all developing countries, including those which do not qualify as LDCs • Users shall be allowed to retain ownership of new intellectual property but are encouraged to make new inventions available through WIPO Re:Search • License Agreements will be individually negotiated between Members in accordance with the Guiding Principles 5
WIPO Re:Search Providers & UsersProviders • U.S. National Institutes of Health• Alnylam Pharmaceuticals • Walter Reed Army Institute of Research (WRAIR)• AstraZeneca Potential Users• California Institute of Technology • Anacor Pharmaceuticals• Center for World Health & Medicine • Center for World Health & Medicine• Drugs for Neglected Diseases initiative • Drugs for Neglected Diseases initiative• Eisai • Emory University• Fundação Oswaldo Cruz (Fiocruz) • Fundação Oswaldo Cruz (Fiocruz)• GlaxoSmithKline • Galvmed• Infectious Disease Research Institute (IDRI) • Infectious Disease Research Institute (IDRI)• Liverpool School of Tropical Medicine • iThemba Pharmaceuticals• Massachusetts Institute of Technology • Liverpool School of Tropical Medicine• McGill University • McGill University• Medicines for Malaria Venture • Medicines for Malaria Venture• Merck • National Center for Genetic Engineering and Biotechnology (BIOTEC)• Northeastern University • Northeastern University• Novartis • PATH• PATH • Sabin Vaccine Institute• Pfizer • South African Medical Research Council• Sanofi • Stanford University• South African Medical Research Council • University of California, Berkeley• Stanford University • University of California, San Francisco• Swiss Tropical and Public Health Institute • University of Dundee• University of California, Berkeley • Walter Reed Army Institute of Research (WRAIR)• University of Dundee 6
WIPO Re:Search Supporters Supporters • Africa Fighting Malaria • Association of University Technology Managers • Biotechnology Industry Organization (BIO) • Council on Health Research for Development (COHRED) • Indian Council for Medical Research • International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) • Kenya Medical Research Institute • Licensing Executive Society International • Mahidol University • South African Medical Research Council • U.S. Patent and Trademark Office • Walter Reed Army Institute of Research (WRAIR) • World Health Organization (WHO) 7
The Partnership Hub The Partnership Hub is the partnering component of WIPO Re:Search • Facilitate collaborations between members to drive the development of drugs, vaccines and diagnostics for neglected tropical diseases, malaria and tuberculosis • Recruit new Members • Actively engage with members to learn about contributions and research needs • Build relationships with members to support their partnering interests 9
BVGH - The Partnership Hub Administrator How does BVGH establish WIPO Re:Search collaborations? • Field member requests • Proactively identify partnership opportunities • Build knowledge of member contributions and research programs • Match contributions and resources with member’s research needs • Facilitate collaboration between members 10
Partnership Hub: Connecting the Spokes• Contribute IP • Search WIPO Provider Re:Search & know-how• Collaborate database• Host & Mentor User • Identify & User communicate resource needs • Collaborate• Identify collaboration Provider Provider opportunities• Connect Users & Providers User• Support Members 11
WIPO Re:Search Collaborations • Various research agreements • material transfer agreements – compound libraries, compounds • confidentiality agreements - sharing data, know-how and other confidential information • Building expertise and capacity through hosting and mentoring arrangements • Licensing agreements • Other agreements to support the development of products for NTDs, malaria and tuberculosis 12
Partnership Hub Resources • Partnership Hub Monthly Snapshot • Partnership Hub activities • Collaborations in the pipeline • Research requests • New and highlighted contributions • Select upcoming member presentations • Quarterly Contribution Highlights • Two page scientific piece highlighting a WIPO Re:Search contribution 13
Partnership Hub Resources • Communications “tool-kit” • WIPO Re:Search slide set • One page overview for scientists • One page overview for policy makers • WIPO Re:Search flyer/brochure • WIPO Re:Search scientific poster • List of key neglected tropical disease meetings • WIPO Re:Search Database 14
WIPO Re:Search Database WIPO Re:Search provides a searchable, public database of intellectual property, know-how and other resources • Compounds • Compound libraries • Technologies • Know-how and therapeutic area expertise • Hosting and mentoring scientists at various research and development sites • Coaching scientists 15
Structured search by… Provider Disease Type of data
Potential Collaborations AstraZeneca and iThemba • iThemba developing isocitrate lyase inhibitors for Tuberculosis • AstraZeneca is open to considering neglected tropical disease research requests to support computational and predictive chemistry needs • iThemba expressed interest in accessing computational support to improve DMPK properties About 1.9 billion people have latent TB. According to the WHO approximately 1.4 million people died of TB in 2010. 19
Potential CollaborationsMcKerrow Lab at UCSF interested in statins forSchistosomiasis • Interest in compounds selective for parasite not human • Pharmaceutical companies such as Merck have developed statins and are exploring availability of compound libraries for UCSF • Statins going off patent Schistosomiasis is caused by parasitic worms >207 million affected, 85% in Africa (WHO) 20
Potential Collaborations Emory Vaccine Center and Sabin Vaccine Institute • Emory scientists have expertise in system vaccinomics (how vaccines affect innate and adaptive immunity and biomarker identification). • Sabin is developing hookworm, schistosomiasis and Chagas vaccines. • Potential to collaborate to better understand vaccine effect on immunity and to improve vaccine design. 21
Selected Contributions in Database Alnylam • More than 1,500 issued or pending RNAi patents, with know-how and expertise AstraZeneca (AZ) • Host and mentor researchers working on NTD targets at AZ facilities • Screening of targets against AZ compound libraries GlaxoSmithKline (GSK) • Contributed full antimalarial dataset (13,500 compounds) • Tres Cantos Open Lab Program Merck • Casein Kinase I Inhibitors against Leishmaniasis (lead series) • Histone Deacetylase (HDAC) inhibitor series - malaria Check out http://www.wipo.int/research/en/search/ for additional contributions 22